大発作治療の世界市場レポート 2025年

大発作治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.7％で26億3,000万米ドルに成長します。予測期間の成長は、遺伝子研究と精密医療、遠隔治療のための遠隔医療、アクセシビリティの規制変更、脳画像技術の強化、治療への全人的アプローチに起因すると考えられます。予測期間中の世界の動向としては、てんかん啓発のための世界のアドボカシー活動、患者中心のケアモデル、発作遺伝学の研究拡大、コミュニティ支援ネットワーク、非薬物療法アプローチなどが挙げられます。

大発作治療市場の成長予測は、てんかんの高い有病率の影響を強く受けています。てんかんは、繰り返し起こる発作を特徴とする神経疾患で、特に激しく暴力的な大発作として現れることが多いです。てんかんの有病率が世界的に上昇していることから、大発作に特化した治療法の改善が急務となっています。2023年2月現在、世界保健機関（WHO）の報告によると、てんかん患者数は全世界で約5,000万人に上り、世界的に最も有病率の高い神経疾患の1つとなっています。てんかんの年間診断率は約500万人であり、てんかん有病率の増加は大発作治療市場の成長を促進する主要因となっています。

大発作治療市場の成長軌道は、個別化医療の採用増加によってさらに促進されます。革新的なヘルスケアアプローチである個別化医療は、個々の患者の特性に合わせた治療を行います。大発作治療でいう個別化医療とは、個人の遺伝子や分子プロファイルを分析し、患者固有の特徴に基づいて、より効果的で忍容性の高い薬剤を選択するなど、介入方法をカスタマイズすることです。この精度を重視したアプローチにより、患者ごとの副作用を最小限に抑えながら発作の制御を強化できる可能性があります。2022年、米国食品医薬品局（FDA）の医薬品評価研究センター（CDER）は37の新規分子化合物（NME）を承認し、そのうち約34％にあたる12のNMEが個別化医療連合（PMC）によって個別化医療に分類されました。このような個別化医療の大幅な導入が、大発作治療市場の成長を促進する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界大発作治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の大発作治療市場：成長率分析
• 世界の大発作治療市場の実績：規模と成長, 2019-2024
• 世界の大発作治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界大発作治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の大発作治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バルビツール酸
• ヒダントイン
• フェニルトリアジン
• イミノスチルベン
• ベンゾジアゼピン
• 脂肪族カルボン酸
• その他のタイプ
• 世界の大発作治療市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 磁気共鳴画像（MRI）
• 脳波（EEG）
• 血液検査
• コンピュータ断層撮影（CT）
• その他の診断
• 世界の大発作治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗てんかん薬
• 手術
• 迷走神経刺激
• ケトジェニックダイエット
• その他の治療法
• 世界の大発作治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 学術研究センター
• 神経センター
• 病院
• その他のエンドユーザー
• 世界の大発作治療市場、バルビツール酸のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェノバルビタール
• プリミドン
• 世界の大発作治療市場、ヒダントインの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェニトイン
• 世界の大発作治療市場、フェニルトリアジンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラモトリギン
• 世界の大発作治療市場、イミノスチルベンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルバマゼピン
• オクスカバゼピン
• 世界の大発作治療市場ベンゾジアゼピンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロナゼパム
• ジアゼパム
• ロラゼパム
• 世界の大発作治療市場、脂肪族カルボン酸の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バルプロ酸
• ジバルプロエックスナトリウム
• 世界の大発作治療市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• レベチラセタム
• トピラマート
• ゾニサミド

第7章 地域別・国別分析

• 世界の大発作治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の大発作治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 大発作治療市場：競合情勢
• 大発作治療市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• UCB Celltech Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Lupin Pharmaceuticals Inc.
• Dr. Reddy's Laboratories Ltd.
• Cipla Inc.
• Apotex Inc.
• Hikma Pharmaceuticals PLC
• Alkem Laboratories Ltd.
• Jubilant Life Sciences Limited
• Torrent Pharmaceuticals Ltd.
• Zydus Cadila
• Strides Pharma Science Limited
• Glenmark Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 大発作治療市場2029：新たな機会を提供する国
• 大発作治療市場2029：新たな機会を提供するセグメント
• 大発作治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for grand mal seizures involves medical interventions and management strategies aimed at controlling or minimizing the impact of tonic-clonic seizures on an individual's life. The goal is to prevent or reduce the frequency, duration, and intensity of seizures while mitigating potential medication side effects.

Key categories of grand mal seizure treatments include barbiturates, hydantoin, phenyltriazine, iminostilbenes, benzodiazepines, aliphatic carboxylic acids, and other medication classes. Barbiturates function as central nervous system depressants, serving as sedatives, hypnotics, and anticonvulsants. Diagnosis methods may encompass magnetic resonance imaging (MRI), electroencephalogram (EEG), blood tests, computed tomography (CT), and other diagnostic procedures. Treatment options include antiepileptic drugs, surgical interventions, vagus nerve stimulation, ketogenic diet, among others. These treatments cater to various end-users, including academic and research centers, neurological facilities, hospitals, and other healthcare providers.

The grand mal seizure treatment market research report is one of a series of new reports from The Business Research Company that provides grand mal seizure treatment market statistics, including grand mal seizure treatment industry global market size, regional shares, competitors with a grand mal seizure treatment market share, detailed grand mal seizure treatment market segments, market trends and opportunities, and any further data you may need to thrive in the grand mal seizure treatment industry. This grand mal seizure treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The grand mal seizure treatment market size has grown strongly in recent years. It will grow from $2 billion in 2024 to $2.1 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to neurological understanding, medical advancement, medication development, development of seizure classification, and legal and social advocacy

The grand mal seizure treatment market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to genetic research and precision medicine, telemedicine for remote care, regulatory changes in accessibility, enhanced brain imaging techniques, holistic approach to treatment. Major trends in the forecast period include global advocacy for epilepsy awareness, patient-centered care models, expanded research in seizure genetics, community support networks, and non-pharmacological treatment approaches.

The anticipated growth of the grand mal seizure treatment market is strongly influenced by the high prevalence of epilepsy. Epilepsy, a neurological disorder characterized by recurring seizures, often manifests as grand mal seizures, which are particularly intense and violent. The rising prevalence of epilepsy worldwide underscores the pressing need for improved treatment options, specifically tailored to address grand mal seizures. As of February 2023, the World Health Organization reported that approximately 50 million people globally were grappling with epilepsy, marking it as one of the most prevalent neurological conditions globally. With an annual diagnosis rate of about 5 million people, the escalating prevalence of epilepsy serves as a primary driver fueling the growth of the grand mal seizure treatment market.

The growth trajectory of the grand mal seizure treatment market is further propelled by the increasing adoption of personalized medicines. Personalized medicine, an innovative healthcare approach, tailors medical treatments to the unique characteristics of individual patients. In the context of grand mal seizure treatment, personalized medicine involves analyzing an individual's genetic and molecular profile to customize interventions, such as selecting medications that are likely to be more effective and better tolerated based on the patient's unique characteristics. This precision-driven approach holds the potential to enhance seizure control while minimizing adverse effects for each patient. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), and approximately 34% of these, amounting to 12 NMEs, were classified as personalized medicines by the Personalized Medicine Coalition (PMC). This significant adoption of personalized medicine practices is a key factor driving the growth of the grand mal seizure treatment market.

Major players in the grand mal seizure treatment market are strategically introducing new products, with a focus on anti-epilepsy medications, to gain a competitive advantage. Anti-epilepsy medications, also known as antiepileptic drugs (AEDs) or anticonvulsants, form a crucial class of pharmaceuticals designed to manage and treat epileptic seizures and related disorders. An illustrative example is Zydus Lifesciences Limited, an India-based pharmaceutical company, which, in January 2023, launched Topiramate extended-release capsules in the U.S. market. Zydus achieved the distinction of being the first company to receive final approval and introduce the product in strengths of USP 25 mg, 50 mg, and 100 mg. These capsules are indicated for epilepsy treatment, specifically as initial monotherapy for patients aged six and older with partial-onset or primary generalized tonic-clonic seizures. Additionally, they are approved for migraine prophylaxis in patients aged 12 and older, marking a significant contribution to the evolving landscape of grand mal seizure treatment.

Major companies actively participating in the grand mal seizure treatment market are advancing product development by introducing advanced offerings, particularly small molecule anticonvulsants for refractory focal onset seizures. Small molecule anticonvulsants, characterized by low molecular weight compounds, are instrumental in preventing or controlling seizures in individuals with epilepsy or other neurological disorders. An exemplar in this domain is Xenon Pharmaceuticals Inc., a Canada-based biopharmaceutical company, which launched the Phase 3 program for XEN1101 in November 2022 with the initiation of the X-TOLE2 clinical trial. This trial aims to investigate the use of XEN1101 as an adjunctive treatment for adult patients with focal epilepsy. XEN1101, a differentiated Kv7 potassium channel opener, has garnered positive Phase 2b clinical data, supporting its progression through late-stage clinical development toward commercialization. The introduction of advanced small molecule anticonvulsants represents a strategic move to establish a competitive edge in the dynamic grand mal seizure treatment market.

In March 2022, UCB, a biopharmaceutical company headquartered in Belgium, completed the acquisition of Zogenix for an estimated $1.9 billion. This strategic acquisition is poised to enable UCB to broaden its portfolio within emerging therapy segments and expand its presence in new geographical regions. Zogenix, based in the United States, specializes in the development and production of medications and therapies targeted at treating grand mal seizures. This acquisition signifies UCB's commitment to advancing its offerings in the treatment landscape for grand mal seizures and expanding its global footprint in the pharmaceutical industry.

Major companies operating in the grand mal seizure treatment market include Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceuticals Inc., Mylan N.V., UCB Celltech Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Cipla Inc., Apotex Inc., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Strides Pharma Science Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Indoco Remedies Limited

North America was the largest region in the grand mal seizure treatment market in 2024. The regions covered in the grand mal seizure treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the grand mal seizure treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The grand mal seizure treatment market consists of revenues earned by entities by providing deep brain stimulation, complementary therapies, and surgical procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The grand mal seizure treatment market also includes sales of brivaracetam, carbamazepine, clobazam, and felbamate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Grand Mal Seizure Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on grand mal seizure treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for grand mal seizure treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The grand mal seizure treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Barbiturates; Hydantoin; Phenyltriazine; Iminostilbenes; Benzodiazepines; Aliphatic Carboxylic Acids; Other Types
• 2) By Diagnosis: Magnetic Resonance Imaging (MRI); Electroencephalogram (EEG); Blood Tests; Computed Tomography (CT); Other Diagnosis
• 3) By Treatment: Antiepileptic Drugs; Surgery; Vagus Nerve Stimulation; Ketogenic Diet; Other Treatments
• 4) By End Users: Academic And Research Centers; Neurological Centers; Hospitals; Other End Users
• Subsegments:
• 1) By Barbiturates: Phenobarbital; Primidone
• 2) By Hydantoins: Phenytoin
• 3) By Phenyltriazines: Lamotrigine
• 4) By Iminostilbenes: Carbamazepine; Oxcabazepine
• 5) By Benzodiazepines: Clonazepam; Diazepam; Lorazepam
• 6) By Aliphatic Carboxylic Acids: Valproic Acid; Divalproex Sodium
• 7) By Other Types: Levetiracetam; Topiramate; Zonisamide
• Companies Mentioned: Novartis AG; Sanofi S.A.; GlaxoSmithKline PLC; Takeda Pharmaceuticals Inc.; Mylan N.V.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Grand Mal Seizure Treatment Market Characteristics

3. Grand Mal Seizure Treatment Market Trends And Strategies

4. Grand Mal Seizure Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Grand Mal Seizure Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Grand Mal Seizure Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Grand Mal Seizure Treatment Market Growth Rate Analysis
• 5.4. Global Grand Mal Seizure Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Grand Mal Seizure Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Grand Mal Seizure Treatment Total Addressable Market (TAM)

6. Grand Mal Seizure Treatment Market Segmentation

• 6.1. Global Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Barbiturates
• Hydantoin
• Phenyltriazine
• Iminostilbenes
• Benzodiazepines
• Aliphatic Carboxylic Acids
• Other Types
• 6.2. Global Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Magnetic Resonance Imaging (MRI)
• Electroencephalogram (EEG)
• Blood Tests
• Computed Tomography (CT)
• Other Diagnosis
• 6.3. Global Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiepileptic Drugs
• Surgery
• Vagus Nerve Stimulation
• Ketogenic Diet
• Other Treatments
• 6.4. Global Grand Mal Seizure Treatment Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Academic And Research Centers
• Neurological Centers
• Hospitals
• Other End Users
• 6.5. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Barbiturates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenobarbital
• Primidone
• 6.6. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Hydantoins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phenytoin
• 6.7. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Phenyltriazines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lamotrigine
• 6.8. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Iminostilbenes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carbamazepine
• Oxcabazepine
• 6.9. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Benzodiazepines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clonazepam
• Diazepam
• Lorazepam
• 6.10. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Aliphatic Carboxylic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Valproic Acid
• Divalproex Sodium
• 6.11. Global Grand Mal Seizure Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levetiracetam
• Topiramate
• Zonisamide

7. Grand Mal Seizure Treatment Market Regional And Country Analysis

• 7.1. Global Grand Mal Seizure Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Grand Mal Seizure Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Grand Mal Seizure Treatment Market

• 8.1. Asia-Pacific Grand Mal Seizure Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Grand Mal Seizure Treatment Market

• 9.1. China Grand Mal Seizure Treatment Market Overview
• 9.2. China Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Grand Mal Seizure Treatment Market

• 10.1. India Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Grand Mal Seizure Treatment Market

• 11.1. Japan Grand Mal Seizure Treatment Market Overview
• 11.2. Japan Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Grand Mal Seizure Treatment Market

• 12.1. Australia Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Grand Mal Seizure Treatment Market

• 13.1. Indonesia Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Grand Mal Seizure Treatment Market

• 14.1. South Korea Grand Mal Seizure Treatment Market Overview
• 14.2. South Korea Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Grand Mal Seizure Treatment Market

• 15.1. Western Europe Grand Mal Seizure Treatment Market Overview
• 15.2. Western Europe Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Grand Mal Seizure Treatment Market

• 16.1. UK Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Grand Mal Seizure Treatment Market

• 17.1. Germany Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Grand Mal Seizure Treatment Market

• 18.1. France Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Grand Mal Seizure Treatment Market

• 19.1. Italy Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Grand Mal Seizure Treatment Market

• 20.1. Spain Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Grand Mal Seizure Treatment Market

• 21.1. Eastern Europe Grand Mal Seizure Treatment Market Overview
• 21.2. Eastern Europe Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Grand Mal Seizure Treatment Market

• 22.1. Russia Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Grand Mal Seizure Treatment Market

• 23.1. North America Grand Mal Seizure Treatment Market Overview
• 23.2. North America Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Grand Mal Seizure Treatment Market

• 24.1. USA Grand Mal Seizure Treatment Market Overview
• 24.2. USA Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Grand Mal Seizure Treatment Market

• 25.1. Canada Grand Mal Seizure Treatment Market Overview
• 25.2. Canada Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Grand Mal Seizure Treatment Market

• 26.1. South America Grand Mal Seizure Treatment Market Overview
• 26.2. South America Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Grand Mal Seizure Treatment Market

• 27.1. Brazil Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Grand Mal Seizure Treatment Market

• 28.1. Middle East Grand Mal Seizure Treatment Market Overview
• 28.2. Middle East Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Grand Mal Seizure Treatment Market

• 29.1. Africa Grand Mal Seizure Treatment Market Overview
• 29.2. Africa Grand Mal Seizure Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Grand Mal Seizure Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Grand Mal Seizure Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Grand Mal Seizure Treatment Market Competitive Landscape And Company Profiles

• 30.1. Grand Mal Seizure Treatment Market Competitive Landscape
• 30.2. Grand Mal Seizure Treatment Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis

31. Grand Mal Seizure Treatment Market Other Major And Innovative Companies

• 31.1. UCB Celltech Ltd.
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Aurobindo Pharma Limited
• 31.5. Lupin Pharmaceuticals Inc.
• 31.6. Dr. Reddy's Laboratories Ltd.
• 31.7. Cipla Inc.
• 31.8. Apotex Inc.
• 31.9. Hikma Pharmaceuticals PLC
• 31.10. Alkem Laboratories Ltd.
• 31.11. Jubilant Life Sciences Limited
• 31.12. Torrent Pharmaceuticals Ltd.
• 31.13. Zydus Cadila
• 31.14. Strides Pharma Science Limited
• 31.15. Glenmark Pharmaceuticals Ltd.

32. Global Grand Mal Seizure Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Grand Mal Seizure Treatment Market

34. Recent Developments In The Grand Mal Seizure Treatment Market

35. Grand Mal Seizure Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Grand Mal Seizure Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Grand Mal Seizure Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Grand Mal Seizure Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer